Information Provided By:
Fly News Breaks for July 26, 2017
NVS, CYRX
Jul 26, 2017 | 08:16 EDT
Janney Capital analyst Paul Knight estimates Cryoport's (CYRX) three year deal to provide Novartis (NVS) shipping and logistics services for CTL019 will yield $8M-$10M of annual revenue, which "locks down" the company's 2018 visibility. He keeps a Buy rating and $8 fair value estimate on Cryoport shares.